指南与共识术前评估与围术期医学疼痛医学

围术期丁丙诺啡管理:PAIN 网络改良 Delphi 临床实践建议

Perioperative Pain and Addiction Interdisciplinary Network (PAIN) clinical practice advisory for perioperative management of buprenorphine: results of a modified Delphi process.
指南 / 共识 · Br J Anaesth · 2019-05-29

该实践建议由围术期疼痛与成瘾跨学科网络(PAIN)采用改良 Delphi 专家共识法制定,核心推荐围术期继续丁丙诺啡治疗,极少需要减量;若辅助镇痛优化后仍镇痛不足,可加用全 μ 激动剂并继续丁丙诺啡。术前须区分慢性疼痛与阿片使用障碍(OUD)指征,OUD 患者应关注长期治疗保留与危害减少。

要点

  • 围术期应继续丁丙诺啡治疗,极少需要减量。
  • 镇痛不足时加用全 μ 激动剂,同时继续丁丙诺啡。
  • 术前区分慢性疼痛与 OUD 指征,个体化处理。

核心结论

  • 围术期主要推荐继续丁丙诺啡治疗,极少需要减量。
  • 镇痛不足时启动全 μ 激动剂并继续丁丙诺啡。
  • OUD 患者需考虑长期治疗保留与危害减少。

研究设计与样本

  • 采用改良 Delphi 专家共识调查技术制定实践建议。

主要发现

  • 专家组就围术期继续丁丙诺啡达成主要推荐。
  • 建议根据镇痛需求决定出院时是否使用全 μ 激动剂。
  • 出院时理想状态为继续丁丙诺啡,但不一定为术前剂量。

关键数值与推荐

  • 主要推荐:围术期继续丁丙诺啡治疗。
  • 极少适合减少丁丙诺啡剂量,与指征或剂型无关。
  • 辅助镇痛优化后仍不足,加用全 μ 激动剂并继续丁丙诺啡。
  • 术前须区分慢性疼痛与 OUD 作为丁丙诺啡主要指征。
  • 临床实践建议主要基于较低级别证据(4 级、5 级)。

临床怎么用

  • 围术期不应常规停用丁丙诺啡。
  • 术前明确丁丙诺啡使用指征以指导围术期管理。
  • 根据镇痛需求个体化决定是否加用全 μ 激动剂及出院方案。

局限性

  • 临床实践建议主要基于较低级别证据(4 级、5 级)。
  • 患者间差异大,需要个体化应用建议。
  • 需进一步研究以改变该患者群体的临床实践行为。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Until recently, the belief that adequate pain management was not achievable while patients remained on buprenorphine was the impetus for the perioperative discontinuation of buprenorphine. We aimed to use an expert consensus Delphi-based survey technique to 1) specify the need for perioperative guidelines in this context and 2) offer a set of recommendations for the perioperative management of these patients. The major recommendation of this practice advisory is to continue buprenorphine therapy in the perioperative period. It is rarely appropriate to reduce the buprenorphine dose irrespective of indication or formulation. If analgesia is inadequate after optimisation of adjunct analgesic therapies, we recommend initiating a full mu agonist while continuing buprenorphine at some dose. The panel believes that before operation, physicians must distinguish between buprenorphine use for chronic pain (weaning/conversion from long-term high-dose opioids) and opioid use disorder (OUD) as the primary indication for buprenorphine therapy. Patients should ideally be discharged on buprenorphine, although not necessarily at their preoperative dose. Depending on analgesic requirements, they may be discharged on a full mu agonist. Overall, long-term buprenorphine treatment retention and harm reduction must be considered during the perioperative period when OUD is a primary diagnosis. The authors recognise that inter-patient variability will require some individualisation of clinical practice advisories. Clinical practice advisories are largely based on lower classes of evidence (level 4, level 5). Further research is required in order to implement meaningful changes in practitioner behaviour for this patient group.

来源:Br J Anaesth,查看原文。版权归原作者所有。

引用

  1. Goel A, Azargive S, Weissman JS, et al. Perioperative Pain and Addiction Interdisciplinary Network (PAIN) clinical practice advisory for perioperative management of buprenorphine: results of a modified Delphi process. Br J Anaesth. 2019. PMID: 31153631. doi:10.1016/j.bja.2019.03.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。